BERLIN (Reuters) – Germany’s CureVac announced on Monday that it has enrolled the first participant in the Phase 2b/3 study of its COVID-19 vaccine candidate.
The trial will assess the safety and efficacy in adults and is expected to include more than 35,000 participants in Europe and Latin America, it added in a statement https://bit.ly/37dwzo4.
(Reporting by Thomas Seythal; Editing by Shri Navaratnam)
